Hospitalizations in Patients Receiving Durvalumab Plus Platinum–Etoposide in First-Line Treatment of Extensive-Stage Small-Cell Lung Cancer: Exploratory Analysis From the Phase IIIb Cantabrico Study

Speaker(s)

Isla D1, Arriola E2, García-Campelo R3, Martí C4, Diz P5, López-Brea M6, Moreno AL7, León-Mateos L8, Oramas J9, Gutiérrez V10, Majem M11, Sánchez-Hernández A12, Aguado de la Rosa C13, Álvarez R14, Massutí B15, Moreno A16, Fírvida JL17, Domínguez M18, Sánchez C19, Martínez A18, Baret M18, Paz-Ares L20
1Hospital Clínico Universitario Lozano Blesa, Zaragoza, Zaragoza, Spain, 2Hospital del Mar, Barcelona, Barcelona, Spain, 3Hospital Universitario A Coruña, A Coruña, A Coruña, Spain, 4Hospital Universitario San Juan de Reus, Reus, Tarragona, Spain, 5Complejo Asistencial Universitario de León, León, León, Spain, 6Hospital Universitario Marqués de Valdecilla, Santander, Santander, Spain, 7Hospital Universitario Reina Sofía, Córdoba, Córdoba, Spain, 8Complexo Hospitalario Universitario de Santiago, Santiago de Compostela, A Coruña, Spain, 9Hospital Universitario de Canarias-San Cristóbal de la Laguna, La Laguna, La Laguna, Spain, 10Hospital Regional Universitario Carlos Haya, Málaga, Málaga, Spain, 11Hospital de la Santa Creu i Sant Pau, Barcelona, Barcelona, Spain, 12Consorcio Hospitalario Provincial de Castellón, Castellón de la Plana, Castellón, Spain, 13Hospital Universitario Clínico San Carlos, Madrid, Madrid, Spain, 14Hospital Virgen de la Salud, Toledo, Toledo, Spain, 15Hospital General Universitario de Alicante, Alicante, Alicante, Spain, 16Hospital Galdako-Usansolo, Galdako, Vizcaya, Spain, 17Complejo Hospitalario Universitario de Ourense, Ourense, Ourense, Spain, 18AstraZeneca Farmacéutica Spain, Madrid, Madrid, Spain, 19AstraZeneca Farmacéutica Spain, Madrid, M, Spain, 20Hospital Universitario 12 de Octubre, Madrid, Madrid, Spain

OBJECTIVES: Most patients (pts) with small-cell lung cancer (SCLC) have extensive-stage (ES) disease at diagnosis and poor prognosis. Evidence concerning medical-care consumption among ES-SCLC patients is limited to chemotherapy administration, where average number and duration of hospitalizations during the first two years of treatment could vary between 0.98-1.49 and 11.57-16.94 (days), respectively (O’Sullivan et al 2021). The purpose of this analysis was to identify medical-care consumption in first-line (1L) durvalumab (D) + platinum–etoposide (PE) treatment of ES-SCLC in Spain.

METHODS: CANTABRICO is a phase IIIb, single arm, multicentre study (NCT04712903). Eligible pts were ≥18 years old with treatment-naive ES-SCLC, ECOG PS 0-2, ≥1 measurable lesion. D (1500 mg) was concurrently administered PE every 3 weeks (q3w) for 4-6 cycles, followed by maintenance (q4w) until progressive disease/unacceptable toxicity. Number and duration of hospitalisations have been considered.

RESULTS: Between December 2020 and April 2021, 101 pts from 35 sites in Spain were included with a mean follow-up of 25.5 months. 56% of pts were ≥65 years old, 67% were men and 6% had ECOG 2. 34%, 37% and 11% of pts had liver, bone or brain metastases, respectively.

Regarding use of healthcare resources, less than half of the patients (48/101, 48%) required hospitalisation during treatment, and 60% (29/48) of these patients were hospitalised only once. The mean (standard deviation [SD]) number of hospitalisations recorded in the study was 0.7 (0.9; 0.0–3.0) per patient with a mean (SD) duration of 5.6 (8.8; 0.0–49.0) days.

CONCLUSIONS: CANTABRICO is the first phase IIIb trial of chemoimmunotherapy including healthcare resource use of ES-SCLC in Spain. In CANTABRICO, the use of healthcare resources, such as hospitalisations, appears to be lower compared to previous reports of EP. These results suggest that adding durvalumab to EP for the treatment of ES-SCLC may reduce healthcare resource use.

Code

EE189

Topic

Economic Evaluation

Disease

Drugs, Oncology